What is Brief History of QuidelOrtho Company?

QuidelOrtho Bundle

Get Full Bundle:

	SWOT	$15	$10
	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10

TOTAL:

ADD TO CART

What's the Story Behind QuidelOrtho?

Ever wondered how a QuidelOrtho SWOT Analysis reveals a company's strengths? This diagnostic company has a fascinating past, marked by innovation and strategic moves. From its humble beginnings to its current global presence, QuidelOrtho's journey is a testament to its adaptability and vision in the medical diagnostics field.

The brief history of QuidelOrtho, a leader in medical diagnostics, begins with the founding of Quidel Corporation, setting the stage for a remarkable transformation. Understanding the QuidelOrtho history is crucial for investors and industry watchers alike. This exploration of its company history illuminates the key acquisitions and innovations that have shaped its trajectory, offering insights into its enduring impact on healthcare.

The story of QuidelOrtho Corporation is a tale of two companies, Quidel Corporation and Ortho Clinical Diagnostics, merging to create a significant player in the medical diagnostics field. This merger combined the strengths of both entities, leading to the formation of what is known today as QuidelOrtho.

Understanding the QuidelOrtho history requires looking at the origins of its predecessors. Quidel Corporation's roots trace back to 1979, while Ortho Clinical Diagnostics has a history that began in 1939. The eventual merger in 2022 created a diagnostic company with a broad portfolio of products and services.

The brief history of QuidelOrtho merger highlights a strategic combination of expertise and resources. This union has positioned QuidelOrtho to address the evolving needs of the healthcare industry.

Founding Story

Quidel Corporation was initially established in 1979 in San Diego, California, under the name Hybritech, Inc., founded by Walt M. Blizzard. Quidel was later formed in 1991 through the merger of Quidel and Monoclonal Antibodies, with Dr. David H. Katz, M.D., recognized as a founder. Quidel commenced operations in 1981 and launched its first products in 1984.

• Ortho Clinical Diagnostics began in 1939 as Ortho Products, Inc., a division of Johnson & Johnson, in Linden, New Jersey.
• It focused on products and diagnostic equipment for blood testing.
• In 1994, Johnson & Johnson acquired Eastman Kodak's Clinical Diagnostics Division, merging it with Ortho Diagnostic Systems in 1997.
• The Carlyle Group purchased Ortho Clinical Diagnostics from Johnson & Johnson in 2014 for $4.15 billion.

The QuidelOrtho company timeline culminates in 2022, when Quidel Corporation acquired Ortho Clinical Diagnostics Holdings for $6 billion. This acquisition brought together their complementary strengths in diagnostic testing solutions. The merger aimed to create a more comprehensive offering in the medical diagnostics market. To understand the target market of the combined entity, you can read more about it in this article: Target Market of QuidelOrtho.

QuidelOrtho SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

The early years of the diagnostic company Quidel saw significant expansion through product launches and strategic acquisitions. This growth trajectory is a key part of the QuidelOrtho history, shaping its position in the medical diagnostics market. These moves broadened its capabilities and market reach, laying the groundwork for its future as a leader in the industry. Understanding this early expansion is crucial for grasping the full scope of the QuidelOrtho company timeline.

Quidel's Early Product Launches

In 1997, Quidel launched the QuickVue® One-Step Strep A Test, expanding its immunoassay product line. The company enhanced its cardiac marker tests with the launch of the Delfia® Xpress PlGF assay in 2002. Further strengthening its molecular diagnostics, Quidel received FDA clearance for the AmplVue™ hMPV Assay in 2010. These launches are key examples of QuidelOrtho's main products.

Strategic Acquisitions by Quidel

Quidel's acquisition strategy significantly impacted its growth. The acquisition of Metra Biosystems, Inc. in 1999 broadened its rapid diagnostic test portfolio. In 2006, the company acquired Diagnostic Hybrids, Inc., expanding its molecular diagnostic capabilities. The 2013 acquisition of Alere Inc.'s Triage® MeterPro assets expanded point-of-care diagnostics. The acquisition of Trek Diagnostic Systems in 2017 added to its microbiology offerings. These acquisitions are a crucial part of the QuidelOrtho history.

Ortho Clinical Diagnostics' Milestones

Ortho Clinical Diagnostics introduced the first hepatitis C antibody test in 1989. In 2003, it launched the Ortho ProVue®, the first fully automated immunohematology system for use with the ID-Micro Typing System™ (ID-MTS) Gel Test in North America. These developments highlight Ortho's contributions to medical diagnostics.

The Quidel and Ortho Merger

The merger of Quidel Corporation and Ortho Clinical Diagnostics in May 2022 for $6 billion created QuidelOrtho Corporation. This merger is a pivotal moment in the brief history of QuidelOrtho merger, establishing a global leader in in vitro diagnostics. The combination brought together a diversified portfolio, including point-of-care settings, clinical labs, and transfusion medicine. You can find more details about this merger in this article about QuidelOrtho.

QuidelOrtho PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

The QuidelOrtho company history is marked by significant events and strategic shifts. This diagnostic company has evolved through mergers and innovations, impacting the medical diagnostics field significantly. Understanding the QuidelOrtho history provides insights into its current market position and future prospects.

QuidelOrtho has consistently introduced innovative diagnostic tools. These innovations have significantly improved the speed and accuracy of medical testing, contributing to better patient outcomes and more efficient healthcare practices.

Rapid Diagnostic Tests

Quidel’s development of rapid diagnostic tests, such as the QuickVue® Influenza Test A+B, has revolutionized the way infectious diseases are detected. These tests provide quick results, enabling timely treatment and containment of outbreaks.

Automated Immunohematology Systems

Ortho Clinical Diagnostics’ introduction of the Ortho ProVue® system marked a significant advancement in blood typing. This automation streamlined the process and improved the accuracy of blood transfusions.

COVID-19 Rapid Antigen Tests

The FDA's EUA for Quidel’s COVID-19 rapid antigen test was a critical innovation during the pandemic. These tests provided a fast and effective way to screen for the virus, aiding in public health efforts.

Sofia SARS Antigen+ FIA

The Sofia SARS Antigen+ FIA, which received CLIA Waiver in 2023, exemplifies QuidelOrtho's commitment to providing accessible and accurate diagnostic solutions. This test allows for rapid detection of SARS-CoV-2.

LEX Diagnostics Acquisition

The planned acquisition of LEX Diagnostics, with its ultra-fast molecular platform, is a forward-looking innovation. This technology promises to deliver rapid results for Flu A, Flu B, and COVID-19 detection in approximately six minutes, enhancing QuidelOrtho's diagnostic capabilities.

Savanna Platform Discontinuation

The decision to discontinue the Savanna platform development, influenced by recent clinical trial results, reflects a strategic realignment of the product portfolio. This move allows QuidelOrtho to focus resources on more promising technologies.

QuidelOrtho has faced several challenges that have influenced its strategic direction. The acquisition of LEX Diagnostics and the discontinuation of the Savanna platform underscore the company's efforts to adapt to market dynamics and technological advancements.

Revenue Decline

In 2024, QuidelOrtho reported a decrease in revenue, with total revenue at $2.78 billion, a 7% decrease compared to the prior year. This decline was primarily due to lower revenues from COVID-19 and influenza tests.

GAAP Net Loss

The company reported a GAAP net loss of $2.03 billion for the full year 2024. This significant loss was largely impacted by a non-cash goodwill impairment charge of approximately $1.82 billion.

Strategic Pivot

In response to these challenges, QuidelOrtho announced a strategic pivot in June 2025. This involves acquiring LEX Diagnostics and discontinuing the Savanna platform development to focus on faster molecular diagnostics.

Platform Development

The decision to discontinue the Savanna platform development reflects the challenges in bringing new products to market and the need to realign resources. This shift is aimed at leveraging LEX Diagnostics' technology.

Cost-Saving Initiatives

QuidelOrtho is focused on cost-saving initiatives, anticipating additional procurement-related reductions of $30 million to $50 million in 2025. These measures are crucial for improving financial performance.

Market Competition

The diagnostic company operates in a competitive market, requiring continuous innovation and strategic adjustments. Understanding the Competitors Landscape of QuidelOrtho is essential for assessing its position.

QuidelOrtho Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

The QuidelOrtho history reflects significant milestones in the medical diagnostics industry. From its founding in 1979 as Quidel Corporation to the 2022 acquisition of Ortho Clinical Diagnostics, the company has consistently evolved. Key achievements include the introduction of pioneering diagnostic tests and strategic acquisitions that have shaped its market position. Recent developments, such as the investment in LEX Diagnostics and the refocusing of its molecular diagnostics strategy, signal a commitment to innovation and growth.

Financial Guidance

For fiscal year 2025, QuidelOrtho projects total revenues between $2.60 billion and $2.81 billion. The company anticipates adjusted EBITDA to range from $575 million to $615 million, representing an adjusted EBITDA margin of 22%. This outlook indicates continued financial health and strategic focus.

Strategic Initiatives

QuidelOrtho is focused on several key initiatives, including enhancing operational efficiency through cost-saving measures. They expect an additional $30 million to $50 million in procurement-related reductions in 2025. The company also aims to reduce its leverage ratio between 2.5 and 3.5 and plans to refinance debt in the second half of 2025.

Market Growth

Growth is expected across multiple business segments. Labs and Point of Care (excluding COVID-19) are projected to grow at mid-single-digit rates. China remains a key growth market, with expectations of mid- to high-single-digit expansion. The company forecasts full-year 2025 COVID-19 revenue to be between $110 million and $140 million.

Future Outlook

The acquisition of LEX Diagnostics is a key part of QuidelOrtho's innovation roadmap, aiming to strengthen its presence in the rapidly growing point-of-care molecular diagnostics segment. Analysts have a mixed to optimistic outlook, with an average twelve-month stock price forecast of $44.33, indicating a potential upside of 42.64% from its price of $31.08.

QuidelOrtho Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔

Related Blogs